logo

SCIENTIA SINICA Vitae, Volume 45 , Issue 4 : 340-346(2015) https://doi.org/10.1360/N052014-00338

Progress in Cell Therapy for Parkinson's Disease

More info
  • ReceivedDec 31, 2014
  • AcceptedFeb 13, 2015
  • PublishedApr 20, 2015

Abstract


References

[1] Olanow C W. The scientific basis for the current treatment of Parkinson's disease. Annu Rev Med, 2004, 55: 41-60. Google Scholar

[2] Dick F D, De Palma G, Ahmadi A, et al. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med, 2007, 64: 666-672. Google Scholar

[3] Lees A J, Hardy J, Revesz T. Parkinson's disease. Lancet, 2009, 373: 2055-2066. Google Scholar

[4] Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. New Engl J Med, 2004, 351: 2498-2508. Google Scholar

[5] Marsden C D, Parkes J D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet, 1976, 1: 292-296. Google Scholar

[6] Benabid A L, Chabardes S, Mitrofanis J, et al. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol, 2009, 8: 67-81. Google Scholar

[7] Bensadoun J C, Deglon N, Tseng J L, et al. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp Neurol, 2000, 164: 15-24. Google Scholar

[8] Ren X, Zhang T, Gong X, et al. AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model. Exp Neurol, 2013, 248: 148-156. Google Scholar

[9] Sun Z, Jia J, Gong X, et al. Inhibition of glutamate and acetylcholine release in behavioral improvement induced by electroacupuncture in parkinsonian rats. Neurosci Lett, 2012, 520: 32-37. Google Scholar

[10] Lindvall O, Rehncrona S, Brundin P, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol, 1989, 46: 615-631. Google Scholar

[11] Svendsen C N, Caldwell M A, Shen J, et al. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp Neurol, 1997, 148: 135-146. Google Scholar

[12] Brederlau A, Correia A S, Anisimov S V, et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells, 2006, 24: 1433-1440. Google Scholar

[13] Tabar V, Tomishima M, Panagiotakos G, et al. Therapeutic cloning in individual parkinsonian mice. Nat Med, 2008, 14: 379-381. Google Scholar

[14] Sanchez-Pernaute R, Lee H, Patterson M, et al. Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease. Brain, 2008, 131: 2127-2139. Google Scholar

[15] Hargus G, Cooper O, Deleidi M, et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci USA, 2010, 107: 15921-15926. Google Scholar

[16] Brundin P, Nilsson O G, Strecker R E, et al. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease. Exp Brain Res, 1986, 65: 235-240. Google Scholar

[17] Wenning G K, Odin P, Morrish P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol, 1997, 42: 95-107. Google Scholar

[18] Hagell P, Schrag A, Piccini P, et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain, 1999, 122: 1121-1132. Google Scholar

[19] Politis M, Wu K, Loane C, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med, 2010, 2: 38ra46. Google Scholar

[20] Freed C R, Greene P E, Breeze R E, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New Engl J Med, 2001, 344: 710-719. Google Scholar

[21] Olanow C W, Kordower J H, Freeman T B. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci, 1996, 19: 102-109. Google Scholar

[22] Olanow C W, Goetz C G, Kordower J H, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol, 2003, 54: 403-414. Google Scholar

[23] Hagell P, Piccini P, Bjorklund A, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci, 2002, 5: 627-628. Google Scholar

[24] Piccini P, Pavese N, Hagell P, et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain, 2005, 128: 2977-2986. Google Scholar

[25] Politis M, Oertel W H, Wu K, et al. Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio. Mov Disord, 2011, 26: 1997-2003. Google Scholar

[26] Gage F H, Kempermann G, Palmer T D, et al. Multipotent progenitor cells in the adult dentate gyrus. J Neurobiol, 1998, 36: 249-266. Google Scholar

[27] Altman J, Das G D. Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. J Comp Neurol, 1965, 124: 319-335. Google Scholar

[28] Mckay R. Stem cells in the central nervous system. Science, 1997, 276: 66-71. Google Scholar

[29] Alvarez-Buylla A, Temple S. Stem cells in the developing and adult nervous system. J Neurobiol, 1998, 36: 105-110. Google Scholar

[30] Nishino H, Hida H, Takei N, et al. Mesencephalic neural stem (progenitor) cells develop to dopaminergic neurons more strongly in dopamine-depleted striatum than in intact striatum. Exp Neurol, 2000, 164: 209-214. Google Scholar

[31] Parish C L, Castelo-Branco G, Rawal N, et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest, 2008, 118: 149-160. Google Scholar

[32] Fricker R A, Carpenter M K, Winkler C, et al. Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain. J Neurosci, 1999, 19: 5990-6005. Google Scholar

[33] Schwarz S C, Wittlinger J, Schober R, et al. Transplantation of human neural precursor cells in the 6-OHDA lesioned rats: effect of immunosuppression with cyclosporine A. Parkinsonism Relat Disord, 2006, 12: 302-308. Google Scholar

[34] Evans M J, Kaufman M H. Establishment in culture of pluripotential cells from mouse embryos. Nature, 1981, 292: 154-156. Google Scholar

[35] Thomson J A, Kalishman J, Golos T G, et al. Isolation of a primate embryonic stem cell line. Proc Natl Acad Sci USA, 1995, 92: 7844-7848. Google Scholar

[36] Thomson J A, Itskovitz-Eldor J, Shapiro S S, et al. Embryonic stem cell lines derived from human blastocysts. Science, 1998, 282: 1145-1147. Google Scholar

[37] Kim J H, Auerbach J M, Rodriguez-Gomez J A, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature, 2002, 418: 50-56. Google Scholar

[38] Roy N S, Cleren C, Singh S K, et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med, 2006, 12: 1259-1268. Google Scholar

[39] Kriks S, Shim J W, Piao J, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature, 2011, 480: 547-551. Google Scholar

[40] Lee S H, Lumelsky N, Studer L, et al. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol, 2000, 18: 675-679. Google Scholar

[41] Kawasaki H, Mizuseki K, Nishikawa S, et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron, 2000, 28: 31-40. Google Scholar

[42] Chambers S M, Fasano C A, Papapetrou E P, et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol, 2009, 27: 275-280. Google Scholar

[43] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006, 126: 663-676. Google Scholar

[44] Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007, 131: 861-872. Google Scholar

[45] Yu J, Vodyanik M A, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science, 2007, 318: 1917-1920. Google Scholar

[46] Liu H, Zhu F, Yong J, et al. Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell, 2008, 3: 587-590. Google Scholar

[47] Soldner F, Hockemeyer D, Beard C, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell, 2009, 136: 964-977. Google Scholar

[48] Dimos J T, Rodolfa K T, Niakan K K, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science, 2008, 321: 1218-1221. Google Scholar

[49] Israel M A, Yuan S H, Bardy C, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature, 2012, 482: 216-220. Google Scholar

[50] Wernig M, Lengner C J, Hanna J, et al. A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nat Biotechnol, 2008, 26: 916-924. Google Scholar

[51] Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration. Science, 2008, 322: 945-949. Google Scholar

[52] Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science, 2009, 324: 797-801. Google Scholar

[53] Cheng L, Hansen N F, Zhao L, et al. Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell, 2012, 10: 337-344. Google Scholar

[54] Chung C Y, Khurana V, Auluck P K, et al. Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. Science, 2013, 342: 983-987. Google Scholar

[55] Bianco P, Riminucci M, Gronthos S, et al. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells, 2001, 19: 180-192. Google Scholar

[56] Zipori D. Mesenchymal stem cells: harnessing cell plasticity to tissue and organ repair. Blood Cells Mol Dis, 2004, 33: 211-215. Google Scholar

[57] Trzaska K A, Rameshwar P. Dopaminergic neuronal differentiation protocol for human mesenchymal stem cells. Methods Mol Biol, 2011, 698: 295-303. Google Scholar

[58] Dezawa M, Kanno H, Hoshino M, et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest, 2004, 113: 1701-1710. Google Scholar

[59] Ren Z, Wang J, Wang S, et al. Autologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeys. Sci Rep, 2013, 3: 2786. Google Scholar

[60] Vierbuchen T, Ostermeier A, Pang Z P, et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature, 2010, 463: 1035-1041. Google Scholar

[61] Ieda M, Fu J D, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell, 2010, 142: 375-386. Google Scholar

[62] Szabo E, Rampalli S, Risueno R M, et al. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature, 2010, 468: 521-526. Google Scholar

[63] Pfisterer U, Kirkeby A, Torper O, et al. Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci USA, 2011, 108: 10343-10348. Google Scholar

[64] Caiazzo M, Dell'anno M T, Dvoretskova E, et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature, 2011, 476: 224-227. Google Scholar

[65] Kim J, Su S C, Wang H, et al. Functional integration of dopaminergic neurons directly converted from mouse fibroblasts. Cell Stem Cell, 2011, 9: 413-419. Google Scholar

[66] Sheng C, Zheng Q, Wu J, et al. Generation of dopaminergic neurons directly from mouse fibroblasts and fibroblast-derived neural progenitors. Cell Res, 2012, 22: 769-772. Google Scholar

[67] Liu X, Li F, Stubblefield E A, et al. Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. Cell Res, 2012, 22: 321-332. Google Scholar

[68] Kim J, Efe J A, Zhu S, et al. Direct reprogramming of mouse fibroblasts to neural progenitors. Proc Natl Acad Sci USA, 2011, 108: 7838-7843. Google Scholar

[69] Sheng C, Zheng Q, Wu J, et al. Direct reprogramming of Sertoli cells into multipotent neural stem cells by defined factors. Cell Res, 2012, 22: 208-218. Google Scholar

[70] Wang L, Huang W, Su H, et al. Generation of integration-free neural progenitor cells from cells in human urine. Nat Methods, 2013, 10: 84-89. Google Scholar

[71] Zou Q, Yan Q, Zhong J, et al. Direct conversion of human fibroblasts into neuronal restricted progenitors. J Biol Chem, 2014, 289: 5250-5260. Google Scholar

[72] Kim S M, Flasskamp H, Hermann A, et al. Direct conversion of mouse fibroblasts into induced neural stem cells. Nat Protoc, 2014, 9: 871-881. Google Scholar

[73] Cheng L, Hu W, Qiu B, et al. Generation of neural progenitor cells by chemical cocktails and hypoxia. Cell Res, 2014, 24: 665-679. Google Scholar

[74] Hong J Y, Lee S H, Lee S C, et al. Therapeutic potential of induced neural stem cells for spinal cord injury. J Biol Chem, 2014, 289: 32512-32525. Google Scholar

[75] Wu J, Sheng C, Liu Z, et al. Lmx1a enhances the effect of iNSCs in a PD model. Stem Cell Res, 2015, 14: 1-9. Google Scholar

qqqq

Contact and support